Diurnal Group
在场
是其中之一......
Neurocrine Biosciences 是一家在股票代码 NBIX (US) 下上市的公司。
Neurocrine Biosciences 在 2 个国家有直接业务。
他们在：
涉及Neurocrine Biosciences的并购和融资。
高管
查看带有其 3 名主要高管的组织结构图
Diurnal Group 搜索最多的简介
- John Porter, Medical Director
- Stewart Jones, Operations Director and Head of Chemistry, Manufact...
- Tim Tasker, Vice President, Clinical Development
高管在Neurocrine Biosciences变化
- Kevin Gorman, President, Chief Executive Officer and Director, 将于 202410月11 退休 (新闻发布的2024五月29号).
- Kyle Gano 曾任 Chief Business Development and Strategy Officer, 将于 202410月11 升职为 Chief Executive Officer (新闻发布的2024五月29号).
创建提醒
跟踪 Diurnal Group 的高管变动
药店
Neurocrine Biosciences 拥有 1,841 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Stemtech and Seacret Direct have announced they will merge (公布2024十一月22号)..
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
药店 行业的其他推荐联系人
消息
Diurnal Group 的最新新闻稿
- Notice of Section 338(g) Election - To: Former Shareholders of Diurnal Group Limited (FKA Diurnal Group PLC) | Investor or Media Relations
- AWMSG recommends Efmody® as treatment option for adolescents and adults with congenital adrenal hyperplasia in Wales | Investor or Media Relations
- Interim Results for the Twelve Months Ended 30 June 2022 | Investor or Media Relations
- Trading Update | Investor or Media Relations
- Diurnal to present research into the treatment of CAH at ENDO 2022 | Investor or Media Relations
- First patient dosed in pivotal Phase 3 CONnECT clinical trial for US and Japanese markets | Investor or Media Relations
- Diurnal to present research into the treatment of congenital adrenal hyperplasia at 24th European Congress of Endocrinology meeting | Investor or Media Relations
- Efmody® distribution and marketing agreement signed with EffRx for Switzerland | Investor or Media Relations
- View more press releases Close
关于 Diurnal Group 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 John Porter 
